Table 1.
Baseline characteristics of RA patients treated with etanercept and adalimumab
| Variables | Etanercept (n=2,609) | Adalimumab (n=1,983) | P-value |
|---|---|---|---|
| Sex | 0.170 | ||
| Male | 474 (18.2) | 392 (19.8) | |
| Female | 2,135 (81.8) | 1,591 (80.2) | |
| Age at RA onset, yearsa | 49.2±12.8 | 49.5±12.5 | 0.485 |
| Age at anti-TNF initiation, yearsa | 55.1±13.1 | 55.7±12.6 | 0.143 |
| Age at anti-TNF initiation, ≥65 years | 647 (24.8) | 488 (24.6) | 0.883 |
| RA duration, yearsa | 6.0±3.7 | 6.3±3.7 | 0.005 |
| RA duration, >3 years | 1,831 (70.2) | 1,447 (73.0) | 0.038 |
| History within 1 year before anti-TNF treatment | |||
| Charlson comorbidity index ≥2 | 1,205 (46.2) | 991 (50.0) | 0.011 |
| Methotrexate, >10 mg/wk | 1,460 (56.0) | 1,074 (54.2) | 0.224 |
| Leflunomide | 873 (33.5) | 798 (40.2) | <0.001 |
| Salazopyrin | 1,970 (75.5) | 1,449 (73.1) | 0.061 |
| Hydroxychloroquine | 2,098 (80.4) | 1,544 (77.9) | 0.034 |
| NSAID | 2,587 (99.2) | 1,958 (98.7) | 0.164 |
| Pd equivalent, >5 mg/d | 1,347 (51.6) | 1,039 (52.4) | 0.607 |
Notes: Results are shown as number (%), unless otherwise indicated. The median (IQ range) methotrexate dose during 1 year before anti-TNF treatment was 10.6 (7.3, 13.3) mg/wk.
a
Presented as mean ± SD.
Abbreviations: RA, rheumatoid arthritis; TNF, tumor necrosis factor; NSAID, nonsteroid anti-inflammatory drug; Pd, prednisolone; SD, standard deviation; IQ, interquartile.